RBC gives Seattle Genetics sector perform rating

RBC Capital Markets analyst Jason Kantor reiterated Seattle Genetics Inc. at sector perform, above average risk, on a modest news flow forecast and ahead of clinical data from SGN-30, SGN-40 and SGN-33. Kantor is positive on Seattle Genetics in the long run based on its proprietary pipeline and industry-leading technology. Shares of the Bothell, Wash.-based biotechnology company were down 19 cents, or 3.49%, at $5.27. (Nasdaq: SGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.